

# Ebola PUI: Laboratory Testing & Biosafety Perspective

Megan Price, Ph.D.

Principal Scientist

Bioterrorism & Special Pathogen Response / Molecular Detection and Characterization

Dept. of General Services / Division of Consolidated Laboratory Services


Nov 19, 2018



DEPARTMENT OF  
GENERAL SERVICES

DIVISION OF CONSOLIDATED LABORATORY SERVICES

Serving Government. Serving Virginians.



# Objectives

- ❖ DCLS overview and Ebola Virus response
- ❖ Specimen collection – DCLS testing
- ❖ Specimen transport
- ❖ Specimen packaging & shipping
- ❖ Diagnostic laboratory testing

# Division of Consolidated Laboratory Services (DCLS)

- ❖ Serves as the public health, environmental, agriculture, and consumer protection laboratory for the Commonwealth of Virginia.
- ❖ Serves hundreds of local, state, and federal agencies
- ❖ Perform >7 million tests annually with over 650 different types of analyses
- ❖ Test services include:
  - Microbiology, Mycology, Molecular Biology, Immunology/Virology, Newborn Screening
  - Radiochemistry, comprehensive chemical analyses, food, water, feed, fertilizer analyses
  - Metal/pesticide analyses, motor fuels and commodities analyses, laboratory certification
- ❖ Operate a statewide courier that provides routine and emergency transportation for specimens from over 200 locations to DCLS.
- ❖ Training and education (hospitals and partner agencies)



# DCLS' LRN-Emergency Response Program

- ❖ Only Laboratory Response Network (LRN) Reference laboratory for the Commonwealth of Virginia.
- ❖ Prepare, identify, and respond 24/7/365 to any public health emergency concerning agents of bioterrorism or highly pathogenic, high consequence, or emerging infectious pathogens.
- ❖ Comprised of highly skilled scientists trained and competent to work in BSL-3 containment.
- ❖ Test methods include:
  - Nucleic acid extractions and Real-time PCR assays
  - Conventional, microbial assays
  - Immunoassays
  - Mouse bioassay



# LRN Bio Testing at DCLS

Agent	Disease
<i>Bacillus anthracis</i>	Anthrax
<i>Brucella spp.</i>	Brucellosis
<i>Francisella tularensis</i>	Tularemia
<i>Burkholderia mallei</i> <i>Burkholderia pseudomallei</i>	Glanders Meliodiosis
<i>Yersinia pestis</i>	Plague
<i>Coxiella burnetii</i>	Q fever
Poxviruses	Smallpox, Vaccinia, Chickenpox
Ricin toxin	Ricin poisoning
<i>C. Botulinum</i> & toxins	Botulism

# Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

## LRN –Bio Testing at DCLS

*B. Anthracis*

*Brucella spp.*

*F. tularensis*

*B. mallei & pseudomallei*

*Y. Pestis*

*C. Burnetii*

Poxviruses

Ricin toxin


*C. Botulinum* & toxins

2013 - Novel Coronavirus/ MERS



## HEALTH ADVISORY:

Middle East Respiratory Syndrome (MERS)



### DEVELOPING STORY

#### FIRST MERS CASE IN U.S.

Healthcare worker in Indiana recently was in Saudi Arabia

### DEVELOPING STORY

2ND CASE OF MERS CONFIRMED IN U.S.,  
500 PEOPLE MAY HAVE BEEN EXPOSED



# Ebola Virus Disease

## LRN –Bio Testing at DCLS

*B. Anthracis*

*Brucella* spp.

*F. tularensis*

*B. mallei* & *pseudomallei*

*Y. Pestis*

*C. Burnetii*


Poxviruses

Ricin toxin

*C. Botulinum* & toxins

2013 - Novel Coronavirus/ MERS

2014 - Ebola Zaire Virus



# Zika Virus

## LRN –Bio Testing at DCLS

*B. Anthracis*

*Brucella spp.*

*F. tularensis*

*B. mallei* & *pseudomallei*

*Y. Pestis*

*C. Burnetii*

Poxviruses


Ricin toxin

*C. Botulinum* & toxins

2013 - Novel Coronavirus/ MERS

2014 - Ebola Zaire Virus

2016 - Zika Virus



**ZIKA VIRUS OUTBREAK**  
**36 CASES NOW REPORTED IN 12 STATES**

**BREAKING NEWS** 683 ZIKA CASES IDENTIFIED IN PUERTO RICO - CDC



# DCLS' LRN-Emergency Response Program

## LRN –Bio Testing at DCLS

*B. Anthracis*

*Brucella spp.*

*F. tularensis*

*B. mallei* & *pseudomallei*

*Y. Pestis*

*C. Burnetii*

Poxviruses


Ricin toxin

*C. Botulinum* & toxins

2013 - Novel Coronavirus/ MERS

2014 - Ebola Zaire Virus

2016 - Zika Virus



# DCLS - Ebola Virus Response

# Risk Mitigation - Enhanced PPE

## Standard DCLS BSL-3 PPE:

- ❖ PAPR
- ❖ PAPR head cover
- ❖ Fluid-impervious, back closing gown
- ❖ shoe covers
- ❖ EC gloves (double while working in BSC)



## Enhanced DCLS Ebola testing PPE:

- ❖ Tyvek suit
- ❖ PAPR (inside Tyvek suit)
- ❖ Full PAPR hood (inner bib inside Tyvek suit)
- ❖ Tyvek boots (inside Tyvek suit)
- ❖ Fluid-impervious, back closing gown
- ❖ EC gloves (double while working in BSC)



# Ebola Virus Disease (EVD) Test Approval Process



- ❖ Physician suspects EVD in a PUI with correlated symptoms, travel, and/or exposure history.
- ❖ Physician contacts VDH to discuss suspect case.
- ❖ VDH consults with the CDC.
- ❖ VDH and CDC Ebola SME determine risk classification and decide if Ebola virus testing is warranted.
- ❖ Once approved, VDH contact DCLS to request Ebola virus testing.
- ❖ DCLS contacts hospital to provide specimen collection/packaging guidance and arrange a STAT courier pickup at the healthcare facility.
- ❖ Courier delivers specimen to DCLS for emergency testing.

# DCLS Ebola Virus Testing

## DCLS Ebola Response Team



- ❖ Specialized BSL-3 trained scientists with molecular biology experience.
- ❖ Perform specimen handling, inactivation, and extraction in a restricted BSL-3 containment lab.

## First Tier molecular testing:

- ❖ Ebola virus real-time RT-PCR – detects Ebola Zaire virus
- ❖ Malaria real-time PCR – detects 4 *Plasmodium* species

## Results within 5 hours of specimen receipt at the laboratory

- ❖ False negative EVD results possible when specimen is collected less than 72 hours from symptom onset.
  - If patient remains symptomatic without alternative diagnosis, submit a later specimen to DCLS to rule-out EVD.
- ❖ Any positive EVD result will require confirmation at the CDC.







# DCLS Enhanced Testing Capabilities

## Second Tier molecular testing:

- ❖ Influenza real-time RT-PCR – detects 3 common circulating viruses
- ❖ Norovirus real-time RT-PCR – detects GI and GII genogroups
- ❖ Rapid, molecular GI pathogen panel – 22 GI pathogens  
(bacterial, viral, parasitic)



Additional Testing Capabilities – to provide a comprehensive testing menu in the absence of an alternative diagnosis

- ❖ Arbovirus testing
- ❖ Facilitate shipment of specimens to the CDC for additional or confirmatory testing.

# DCLS Outreach

## DCLS outreach to sentinel hospital laboratories to discuss biosafety, specimen collection and packaging and shipping

- ❖ Provided EVD testing and submission instructions and FAQ documents
  - shared via DCLS website, sentinel lab communications, and in DCLS Ebola kits
- ❖ DCLS Training Coordinators provided on-site, risk assessment training to Virginia hospitals
- ❖ Offer ed free Packaging and Shipping training courses for hospital laboratories
- ❖ Provided Ebola Category A/UN2814 specimen collection and shipping kits to:
  - 35 VDH Health Districts, 5 regional epidemiologists, 4 OCME offices, >100 hospitals, 6 Ebola Assessment Centers, and 2 Ebola Treatment Centers
- ❖ Served on the VDH Ebola Assessment Team and participated in 2016 Ebola Summit
- ❖ Provided 24/7 transport of Ebola virus PUI specimens to DCLS

# Specimen Collection & Transport

# Specimen Collection - DCLS

## Coordinate Ebola PUI testing in collaboration with VDH and DCLS

- ❖ Whole blood preserved with EDTA
- ❖ Plastic tubes only (NO glass)
- ❖ 2 lavender top blood tubes - minimum volume of 4mL each
- ❖ Wear CDC recommended PPE during collection and transport  
<https://www.cdc.gov/vhf/ebola/healthcare-us/ppe/index.html>
- ❖ Do NOT centrifuge or manipulate specimens
- ❖ Specimens should be stored and shipped at 2-8°C



# Specimen Transport In-House

**Pre-plan the route of the specimen from site of care to the testing area**

- ❖ Familiarize staff
- ❖ Avoid high traffic areas
- ❖ Consider providing an escort
- ❖ Wear CDC recommended PPE
- ❖ Hand carry - DO NOT use pneumatic tube systems
- ❖ Use a durable, leak-proof transport container (29 CFR §1910.1030)
- ❖ Decontaminate specimen and outside of transport container with EPA approved disinfectant for Ebola virus before removing from site of care



**Staff training is critical for all aspects of handling patient specimens**



# Specimen Transfer to DCLS

**Ebola Virus is classified by the Department of Transportation (DOT) as a Category A infectious substance**

- ❖ Packaged and shipped in accordance with DOT Hazardous Materials Regulations and International Air Transport Association (IATA) Dangerous Goods Regulations

**Individuals packaging and shipping infectious substances must be trained and certified**

- ❖ Packages require UN-certified materials, labels, marking, and documentation
- ❖ DOT requires recertification every 3 years
- ❖ IATA requires recertification every 2 years

**DCLS Courier –Specimen pickup**


- ❖ Where to park at the facility?
- ❖ Consider convenience to the pickup location
- ❖ Where and whom to meet?

**DCLS Resources**

- ❖ Ebola Virus Disease Testing and Shipping Instructions (# 23539) - DCLS website Hot Topics
- ❖ Micro/Viro Submission Form (# 16857) – DCLS website Resources/Submission Forms
- ❖ Ebola FAQs - DCLS website Hot Topics



# Specimen Packaging & Shipping



# Clinical Diagnostic Testing

# Laboratory Testing: Clinical Care & Differential Diagnosis

**Laboratory testing should NOT be delayed. Timely diagnostic testing is essential to ensure patient care is not compromised.**

- ❖ Use a certified Class II biosafety cabinet (BSC)
- ❖ Proper donning and doffing of CDC recommended PPE is critical for safety
- ❖ Use manufacturer-installed safety features that reduce likelihood of exposure
- ❖ Plan the path of the specimen throughout the testing area and the order of tests
- ❖ Staff training and strict adherence to protocols is essential

**Assessment hospitals must be capable of safely and timely performing the following:**

- ❖ CBC, differential, platelet count
- ❖ Sodium, potassium, bicarbonate, BUN, creatinine, glucose
- ❖ Liver function tests (AST, ALT, total bilirubin)
- ❖ Coagulation testing, especially prothrombin time (PT)
- ❖ Blood culture for bacterial pathogens (manual or automated)
- ❖ Urinalysis (screening test, not requiring centrifugation)
- ❖ Malaria smear or rapid test
- ❖ Rapid Influenza virus testing

# Instruments or methods used in dedicated laboratories to conduct Ebola virus testing

Clinical Chemistry	
<u>Manufacturer</u>	<u>Device</u>
Beckman-Coulter	DxC880i
Abbott Laboratories	ISTAT
Abaxis	Piccolo Xpress

Microbiology	
<u>Test</u>	<u>Method</u>
Blood Culture	Plastic bottle/manual monitoring method
Malaria	Smear fixed in methanol for 15 mins  Alere BinaxNOW

Hematology	
<u>Manufacturer</u>	<u>Device</u>
Sysmex	XN 9000
Sysmex	pocH 100i

Coagulation	
<u>Manufacturer</u>	<u>Device</u>
ITC	Hemochron Signature Elite
F. Hoffman-La Roche	CoaguChek

*These lists are generated from institutions other than DCLS, are for information only and are not intended as a DCLS or CDC endorsement of these instruments or practices, nor should this be considered a complete list of all test instruments that may be acceptable.*



# Site-specific Risk Considerations

## Administrative controls

- ❖ Institutional policies and SOPs, safe work practices, spill response, medical surveillance
- ❖ Training, demonstrating proficiency, spill response
- ❖ PPE selection and use

## Engineering controls

- ❖ BSCs, safety equipment, sealed centrifuge rotors, sharps containers
- ❖ Test area layout, ventilation, anteroom
- ❖ Limit staff, restrict testing area

## Infectious Waste Management

- ❖ EPA requirements for inactivating Ebola Virus

## Instrumentation

- ❖ Certification
- ❖ Ease of operation/use while wearing PPE
- ❖ Aim for closed tube/chamber systems
- ❖ Minimize generation of aerosols
- ❖ Assess potential routes of exposure
- ❖ Consider proximity to other operations
- ❖ Can it be segregated after use
- ❖ Decontamination
- ❖ Will EPA recommended disinfectants affect/interfere with performance or potentially void manufacturer's warranty

# After Ebola Virus

## What will be next???

Public health and health care organizations are better prepared to handle  
the next emerging infectious pathogen



# Questions?

<https://dgs.virginia.gov/division-of-consolidated-laboratory-services>

Email us at:

[megan.price@dgs.virginia.gov](mailto:megan.price@dgs.virginia.gov)

[latoya.griffin-thomas@dgs.virginia.gov](mailto:latoya.griffin-thomas@dgs.virginia.gov)

## **CDC Ebola Virus Disease Guidance for Laboratory Personnel:**

<http://www.cdc.gov/vhf/ebola/healthcare-us/laboratories/index.html>

<http://www.cdc.gov/vhf/ebola/healthcare-us/laboratories/shipping-specimens.html>

<https://www.cdc.gov/vhf/ebola/healthcare-us/ppe/index.html>